The vaccine against SARS-CoV-2 developed by Pfizer Inc. and BioNTech SE could become available for high-risk populations toward the end of this year if the companies are able to secure an emergency use authorization from the US Food and Drug Administration.
The US-based drug maker and German biotech submitted a request to the FDA on 20 November seeking an EUA for...







